The new sites that are now enrolling patients are Montefiore Medical Center (Bronx, NY) and the University of Texas Health Science Center at Houston (Houston, TX).
These sites join existing sites at NYU Langone and the Houston Methodist Research Institute.
The clinical study is designed to evaluate the ability of Humanetics new drug, BIO 300, to mitigate long-term pulmonary damage.
The study will compare the lung function, exercise capacity, and quality of life in COVID-19 survivors who receive BIO 300, against a group receiving a placebo.
BIO 300 is an oral drug that patients self-administer daily for 12 weeks following discharge from the hospital.
The primary endpoint of the trial is 12 weeks after the start of dosing and patients will be followed for one year.
Emerging COVID-19 studies indicate that a high number of infected individuals exhibit signs of lung injury within the first few weeks of infection, and that as many as 50% of patients have signs of pulmonary fibrosis and/or impaired lung function at the time of hospital discharge.
Pulmonary fibrosis results in permanent scarring of the lungs, which can impair breathing and greatly impact a person's quality of life.
BIO 300 is under advanced development as a medical countermeasure to protect the body from harm caused by ionizing radiation. It was initially discovered by researchers at the US Department of Defense in their efforts to create radioprotective drugs for the military.
Humanetics further expanded applications for the drug into cancer radiation therapy and recently completed a clinical trial in lung cancer patients who develop pulmonary injury related to their radiation treatments.
Radiation-induced injury to normal lung tissue in cancer patients is similar to lung injury caused by the COVID-19 virus. BIO 300 has been shown to mitigate inflammation of the lungs and pulmonary fibrosis caused by radiation.
It is believed that the same effect can be shown in COVID-19 patients.
This clinical trial is being funded by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under Contract HHSN272201800011C.
Humanetics is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of proprietary drugs to prevent severe tissue damage caused by exposure to radiation, viral infection and other inflammatory diseases.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial